ABSTRACT
Background and Aims Genetic testing is recommended for select patients with atrial fibrillation (AF). The aims of this study were to define the results of genetic evaluation and its therapeutic impact for patients referred to a dedicated AF precision medicine clinic.
Methods Patients diagnosed with AF before age 60 were candidates for referral. In addition to standard evaluation with history, physical exam, and ECG, genetic evaluation included a 3-generation pedigree, cardiac imaging, ambulatory monitoring, and clinical genetic testing with a cardiomyopathy/arrhythmia panel.
Results 264 participants were referred: the median age was 47 years (Q1, Q3: 38, 55), 77 (29%) were female, and 236 (89%) were White. Median age at AF diagnosis was 39 years (Q1, Q3: 31, 48) and median time from AF diagnosis to evaluation was 3.7 years (Q1, Q3: 0.9, 10). 242 patients (92%) underwent genetic testing, which identified a pathogenic or likely pathogenic variant in 48 (20%). The strongest predictors of positive genetic testing were history of cardiomyopathy, infranodal conduction disease, and elevated T1 or late gadolinium enhancement on cardiac MRI (all p<0.05). The strongest predictors of negative genetic testing were obstructive sleep apnea and a normal 12-lead ECG (both p<0.04). Overall, genetic testing changed clinical management in 52% of patients with positive genetic testing, highlighted by 7 new ICD placements and initiation of disease modifying therapy in 16 patients.
Conclusions Genetic testing was positive in 20% of patients with early-onset AF referred to a dedicated AF precision medicine clinic. Genetic testing results changed clinical management in approximately half of genotype-positive patients.
Key Question Does genetic evaluation of patients with early-onset atrial fibrillation (AF) change their clinical management?
Key Finding Among 246 participants that completed genetic evaluation in a dedicated AF precision medicine clinic, 20% had positive genetic testing with identification of a pathogenic cardiomyopathy or channelopathy variant. These findings led to changes in clinical management in 52% of patients with positive genetic testing.
Take-home Message Genetic evaluation of patients with early-onset AF consists of detailed phenotyping and genetic testing to identify previously undiagnosed genetic disorders. This facilitates earlier diagnosis and clinical intervention.
Competing Interest Statement
Dr. Kanagasundram has received speaking fees from Biosense Webster and Janssen. Dr. Crossley has received consulting fees or honoraria from Bayer Healthcare, Boston Scientific, Janssen Pharmaceuticals, Medtronic, and Spectranetics. Dr. Richardson has received research funding from Medtronic Inc, Abbott Inc and served as a consultant for Philips Inc and Biosense Webster. Dr. Montgomery has received research funding from Medtronic Inc. Dr. Ellis has received research funding from Boston Scientific, Medtronic, Boehringer Ingelheim; and consulting fees from Medtronic, Boston Scientific, Abbott Medical, and Atricure. Dr. W. Stevenson has received Honoria from Abbott, Boston Scientific, Medtronic, Johnson and Johnson and Biotronik and research funding from Adagio Medical. Dr. Tandri has received a research grant from Abbott. The rest of the authors have no disclosures.
Clinical Trial
NCT05190679
Funding Statement
This work was supported by grants from the American Heart Association (AHA) [AHA20SCG35540034 to M.B.S.) and AHA18SFRN34110369 to D.M.R.] and National Institutes of Health (NIH) [R01HL155197 to M.B.S., 1T32HL170965-01 institutional grant supporting J.L.L.]. It was also supported by a National Institutes of Health Clinical and Translational Science Award [UL1TR000445] awarded to Vanderbilt University Medical Center from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the AHA or NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Vanderbilt University Medical Center gave ethical approval for this work (IRB #201666).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY STATEMENT
The data underlying this article cannot be shared publicly for the privacy of patients that participated in the registry. The data will be shared on reasonable request to the corresponding author.
